FDA Budget Proposal Signals Push for Tighter Ad Oversight

Pharmaceutical direct-to-consumer advertisers should treat a legislative proposal in FDA’s recent budget documents (see earlier story) to curb misleading ads as confirmation that enforcement will intensify under this administration.

Under the proposal, FDA seeks authority to deem a drug to be misbranded if a DTC drug advertisement lacks fair balance and creates a misleading impression regarding the approval, the scope of approved indications and the limitations of use, or the drug’s efficacy and benefits, including by making or suggesting overstated representations that are not supported. FDA says it also needs additional authorities to more effectively address DTC advertising that lacks fair balance.

Any legislative proposal has a long road ahead before becoming law, and the results during the upcoming midterm elections could throw a wrench in securing Congressional approval. However, the budget document and associated proposals matter “because it defines the administration’s negotiating position heading into the FY 2027 appropriations cycle and the upcoming user fee reauthorization talks,” law firm Sheppard notes in a blog post about the budget.

The law firm says FDA’s proposal on a new “Expedited Investigational New Drug (IND)” pathway to streamline the launch of Phase 1 clinical trials could be promising. The alternative, risk-based framework would allow certain drug developers to rely more heavily on existing preclinical data — including non-animal testing methods — to meet regulatory requirements. The goal is to reduce development timelines and lower barriers for early-stage research. It notes the proposal could be particularly impactful for smaller biotechnology firms, though its effectiveness will depend heavily on how regulators define acceptable preclinical evidence.

The Sheppard post also found promising FDA’s efforts aimed at encouraging pharmaceutical manufacturing in the U.S. The agency is requesting $9 million in the budget to support its “PreCheck” program intended to accelerate the establishment of domestic manufacturing facilities. In addition, the agency is proposing a legislative change that would give U.S.-based generic drugmakers a one-month head start in filing Paragraph IV patent challenges compared to foreign competitors. Because first-to-file status can lead to 180 days of market exclusivity, the change could provide a meaningful competitive advantage to domestic manufacturers and influence where companies choose to build production capacity, it says.